Ohtuvayre (Ensifentrine) – How does Ensifentrine work?

Ohtuvayre (Ensifentrine) - Ensifentrine is currently the only new drug that may be approved in the near future to treat chronic obstructive pulmonary disease (COPD). This property makes it particularly important to optimize strategies for combining exefentine with appropriate bronchodilators to confirm its actual impact on COPD exacerbations and to clearly assess its anti-inflammatory profile at the airway level. COPD has a serious impact on global health due to persistent airflow limitation and inflammation. Despite standard treatments, many patients continue to suffer from persistent symptoms. Exefentine, a dual phosphodiesterase 3 and 4 inhibitor, targets bronchoconstriction and inflammation, providing promising advances in the treatment of COPD.

Studies have shown that exefantine's affinity forPDE3 is approximately 3,700 times that of PDE4. This feature makes its application in airway smooth muscle particularly effective. In the ENHANCE-1 and ENHANCE-2 trials, exefentine was used in combination with other bronchodilators and showed good effects on FEV1 indicators, although the minimal clinically important difference (>60ml) set by other active treatment regimens was not achieved. In the ENHANCE-2 trial, the FEV1 improvement value of the exefentine group was 49ml, showing good efficacy. Additionally, although FEV1 trough is often used in registration trials, FEV1 area under the 0-12 hour curve (rather than FEV1 trough) is considered the more important outcome measure.

Regarding the clinical use of exefentine, some studies have recommended its use in combination with other types of bronchodilators, especially antimuscarinics (such asglycopyrronium), administered twice daily. This combination may optimize the efficacy of exefentine and enhance its inhibitory effect on airway smooth muscle contraction.

Among 206 related studies, 4 studies were finally selected that met the inclusion criteria. Results showed that exefantine significantly improved the mean difference in FEV1 at the 3 mg dose, reaching 40.90 ml (95% confidence interval [CI] 19.65-62.15 ml). Additionally, there was a significant improvement in dyspnea as measured by the Transitional Dyspnea Index (TDI), with a LS mean difference of 0.91 (95% CI: 0.61-1.21), and an improvement in quality of life as measured by the St. George's Respiratory Questionnaire-C (SGRQ-C) score, with a LS mean difference of -1.92 (95% CI: -3.28 to -0.55). Of note, the safety profile of the exefantine group was similar to that of the placebo group, with no significant increase in treatment-related adverse events (TEAEs) (RR: 1.02; 95% CI: 0.94-1.10).

To sum up, exefantine is improvingCOPD patients showed significant advantages in lung function, reduced dyspnea, and improved quality of life, especially at the 3 mg dose. These benefits, coupled with its stable safety profile, support exefentine as an effective adjunctive therapy in the treatment of COPD. Future studies will further explore its combination with other drugs and its therapeutic effects in different patient groups. By continuing to optimize the treatment plan, Ensefentin is expected to bring a more effective treatment experience to the majority of COPD patients and improve their quality of life.

Reference materials:https://pubmed.ncbi.nlm.nih.gov/39557208/

Reference materials:https://pmc.ncbi.nlm.nih.gov/articles/PMC10806426/